Welcome to Men's Health Focus.
Please log in or register to view the content of this site.
This website provides free access to a range of men’s health related resources and has been developed by EPG Online with an educational grant and assistance from Bayer HealthCare Pharmaceuticals. The content of this site is intended for doctors and other healthcare professionals.
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- February 2014 - Testosterone treatment in obese hypogonadal men with type 2 diabetes
- Treatment with testosterone undecanoate (TU) 1,000 mg was followed for up to 6 years, the longest follow-up period to date.
- In total, 156 obese (BMI ≥30 kg/m2) hypogonadal men with T2DM and dyslipidemia, aged between 41–73 years, were investigated
- TU significantly and progressively improved anthropometric parameters of obesity over 6 years
- Waist circumference (p<0.0001), actual body weight (p=0.001), percentage body weight change (p<0.0001), and BMI (p<0.0001) were improved over 6 years compared with baseline and each year compared to previous year
- TU progressively and significantly decreased levels of HbA1c by a mean of 1.93 ± 0.06% over 6 years (p<0.0001) and each year compared to previous year
- Measures of BP, lipid profiles, liver enzymes, and levels of inflammatory biomarkers were significantly improved after 6 years
- Mean improvements in systolic (23.15 ± 0.83 mmHg) and diastolic (15.07 ± 0.8 mmHg) BP reached a level of statistical significance (p<0.0001) at 3 years, and were sustained for 6 years
- Improvements in HDL-C (+35.03 ± 5.11%), total cholesterol (–32.12 ± 1.41%), LDL-C (–25.93 ± 1.63%), triglycerides (–29.91 ± 2%), liver enzymes aspartate transaminase (12.01 ± 1.33 U/L) and alanine transaminase (12.46 ± 1.83 U/L), and the inflammatory marker C-reactive protein (2.88 ± 0.28 U/L) were gradual and significant (all p<0.0001)
If you are a healthcare professional and would like to gain free access to menshealthfocus.com you must register or login with your EPG Online username and password.
For your information, the menshealthfocus.com website concentrates on the understanding, management and treatment of erectile dysfunction and hypogonadism. The website also provides extensive details on up-coming conferences as well as an extensive library of useful resource.
THIS WEBSITE (www.menshealthfocus.com) IS OWNED AND OPERATED BY EPG HEALH MEDIA (EUROPE) LTD.